Emergent BioSolutions (EBS) Misses Q1 EPS by 25c

Emergent BioSolutions (NYSE: EBS) reported Q1 EPS of ($0.03), $0.25 worse than the analyst estimate of $0.22. Revenue for the quarter came in at $117.8 million versus the consensus estimate of $140.42 million.

For earnings history and earnings-related data on Emergent BioSolutions (EBS) click here.

You May Also Be Interested In

• Wolverine World Wide (WWW) Tops Q2 EPS by 2c; offers guidance
• 22nd Century Group (XXII) Misses Q2 EPS by 9800c
• YETI Holdings, Inc. (YETI) Tops Q2 EPS by 12c